Summary.-The blastogenic response of autologous blood lymphocytes to whole-cell suspensions and to homogenates obtained from malignant lymphoma tissue has been investigated. Spleens were obtained from patients in whom laparotomy was performed for staging of malignant lymphoma. Cell suspensions prepared from tumour nodules were treated with mitomycin C and allowed to react with separated autologous blood lymphocytes for 6 days. Lymphocyte stimulation was measured by liquid scintillation counting after exposure to 3H-TdR. Cultures were also prepared in which autologous lymphocytes were treated with spleen tumour homogenate. Control experiments used spleens from staging procedures in which no tumour deposits were present, and normal spleens removed incidentally during other operations.
MANY human tumours have been shown to have antigenic differences from normal autologous cells (Lewis, 1967; Morton et al., 1968; Helistrom et al., 1971) . Immunization to these antigens may occur in vivo (Powles, Balchin and Fairley, 1971) and sensitized lymphocytes may be detected by a blastogenic response on confrontation with whole tumour cells or tumour extracts (Mavligit et al., 1973; Vanky et al., 1974) , using methods similar to those used in a one-way mixed lymphocyte reaction (Bach and Voynow, 1966) . Positive reactions have been observed in various types of carcinoma, sarcoma, malignant melanoma and leukaemia.
We thought that similar investigations would be ofvalue in malignant lymphomas, especially in view of the variety of cell types seen in histological examination of Hodgkin's disease, in which some almost certainly represent host activity. We have therefore investigated the response of autologous lymphocytes to lymphoma cell suspensions and to subcellular preparations of lymphoma tissue.
MATERIALS AND METHODS
Patients.-Spleens were obtained from patients in whom laparotomy was performed in order to stage the anatomical extent of malignant lymphoma or to provide the initial diagnosis, from patients in whom the spleen was removed for other non-neoplastic haematological diseases, and from patients in whom a histologically normal spleen was removed during the course of another operation (e.g. resection of carcinoma of the stomach). Lymph node tissue was also used on one occasion. All patients were untreated for malignant disease.
All tissues were examined histologically, and both focal nodules, if present, and macroscopically normal areas of spleen were sampled. The Rye Symposium classification was used for Hodgkin's disease (Lukes et al., 1966b ) and Rappaport's classification was adopted for other lymphomas (Rappaport, 1966) .
Tissue cell suspensions.-0-5 g of tissue was finely minced with scissors and forceps in TC 199 (Wellcome Reagents Ltd.) containing 15% heat-inactivated foetal calf serum (Flow Laboratories Ltd.) . Any tumour nodules were dissected to include as little adjacent spleen as possible. The final volume was made up to 50 ml, transferred to a sterile 250-ml Erlenmeyer flask with a loose seal, which was placed in a Mackintosh jar, gassed with 5% Co02 in air, and maintained at 370C until utilized. The cell suspension was counted, and its viability assessed by trypan blue exclusion, the viability always being > 65%.
Tissue cell homogenates.-5 g of tissue was sliced in 25 ml sterile 0.9% saline, homogenized for 15 x 1 min in a sterile MSE atomixer, with water cooling between each burst, and stored at -70°C. Homogenates were checked for bacteriological contamination. Cell reactions.-20 ml of venous blood, anticoagulated with 200 u of preservativefree heparin, was layered on a sterile gradient composed of 9-6 ml of 9% Ficoll (Pharmacia Fine Chemicals) and 4 ml of a solution of Triosil 440 (Nyegaard and Co.) prepared by adding 24 ml water to 20 ml Triosil. The gradient was centrifuged at 600g for 30 min, and the lymphocytes at the interface were removed, washed x 3 in 0.9% sterile saline, and resuspended in culture medium. The cells were counted and assessed for viability, which was always > 90%.
Triplicate 1-ml cultures were set up in tissue culture test tubes, with a final cell concentration of 106lymphocytes/ml in culture medium. Autologous spleen homogenates in protein concentrations of 10-100 ,ug/ml were added to the test cultures. Control cultures contained lymphocytes alone. Heterologous responses, in which spleen homogenates were used to stimulate lymphocytes from normal individuals were also tested.
In the mixed-cell reaction, triplicate 1-ml cultures with equal numbers of peripheral lymphocytes and tissue cells were used at a final concentration of 106 of each cell type/ml. The tissue cell suspensions were treated with 0-25 ,ug/ml mitomycin C (Kyowa Hakko Kogyo Co., Ltd.) at 37°C for 20 min, washed x 5 in sterile 0-9% saline, and resuspended in culture medium. Two types of control cultures were set up: (a) blood lymphocytes alone and (b) mitomycin-treated tissue cells alone. Cultures were maintained at 37°C for 6 or 7 days, 0-2 uCi/ml of 3H-TdR (Radiochemical Centre, Amersham) being present during the last 8 or 16 h of culture. The duration of culture and of exposure to 3H-TdR was always identical in test and control cultures for any one experiment.
Blood lymphocytes were also treated with phytohaemagglutinin (PHA, reagent grade, 0-01 ml/ml) at the same time as carrying out other experiments, in order to test the efficiency of the culture system rather than obtain detailed information on PHA response. These cultures were generally harvested after 3 or 4 days, when maximal stimulation is seen.
The cells were harvested, washed X 3 in 0.9% saline, and precipitated with 5% trichloracetic acid, the precipitates being collected via a millipore sampling manifold on glass filter paper discs (Whatman GF-C), which were then washed with 5% trichloracetic acid followed by absolute ethanol. The discs were dried and placed in a plastic scintillation vial containing 10 ml of scintillation fluid, comprised of PPO, 5g; POPOP, 041 g; and 0-2 ml of hyamine hydroxide, in 1 litre of toluene. The vials were counted in a Packard Scintillation Counter for a minimum of 10 min or 10,000 counts, whichever was first obtained, and the results expressed as ct/min.
A stimulation index (SI) similar to that used by Mavligit et al. (1973) Fig.) . The indices of 4-8, 20-6 and 6-2 are highly significant (P < 0-001), the first 2 being obtained from nodular sclerosing Hodgkin's disease, and the third from follicular lymphoma of lymphocytic type. The 3 indices of 2-2 were obtained from well-differentiated lymphocytic lymphoma, lymphocyte-depleted Hodgkin's disease and " histiocytic " lymphoma.
Homogenate-treated cultures
With tumour-free spleens from patients with malignant lymphoma and with other non-neoplastic spleens (Table I) , the stimulation index ranged from 0-6 to 1*9 with a mean of 1 1 (s.d. 0.4). From " t " tables, 9500 of these control values would be expected to be 1P8 or below, so an index of 2-0 or above was regarded as positive, as for the mixed-cell reactions, and all control figures fell in the negative range.
Positive reactions were seen in 7 out of 16 patients (440 %) in whom tumour was present in the spleen (Table II , Fig.) . The indices of 18-0, 7 0 and 4-5 are highly significant (P < 0-001) and are from nodular sclerosing Hodgkin's disease, mixed cellularity Hodgkin's disease and lymphocytic lymphoma. (Vanky et al., 1974) . In a similar analysis, 19 out of 29 patients with malignant tumours, which included a few lymphomas, showed positive reactions between tumour cells and patient's lymphocytes (Mavligit et al., 1973) and 2 patients responded to a tumour extract. A smaller proportion of positive results was found by Savel (1969) , who obtained significant stimulation in 7 patients out of 56, using a saline extract of tumour; 6 lymphomas of unspecified type were amongst the negative responders and no lymphomas were positive. Positive in vitro reactions have been found in lymphosarcoma and Hodgkin's disease, using the M.I.F. method (Braun et al., 1972) .
In experimental situations of the type we have investigated, a useful control would be to compare the effects of tumour cells and normal cells from the same organ. This is possible if there are reasonably large areas of tumour-free spleen, in addition to the presence oftumour nodules. Our experience to date has been that whenever large dissectable tumour nodules have been present, small nodules have usually been present in the intervening splenic tissue, with the result that it has been possible to perform this control on one occasion only. In this instance, both tumour-containing and tumour-free areas responded negatively.
In the present study, 11 out of 19 patients had a positive response in at least one of the tests employed. It is of interest that of these 11 positive results, 4 were from patients with nodular sclerosing Hodgkin's disease, and only 2 patients with nodular sclerosis had a negative result (Table II) . The numbers are too small to draw any definite conclusions in relation to individual histological types, but it is of note that nodular sclerosis is one of the subvarieties of Hodgkin's disease carrying a better prognosis than average (Lukes, Butler and Hicks, 1966a; Gough, 1970) .
Possible explanations for the reactions are: (a) that blastogenesis occurs in lymphocytes which were presensitized in vivo to an antigenic component of the tumour cell; (b) that lymphocytic stimulation represents a primary immune reaction to a tumour-associated antigen; (c) that lymphocytic stimulation is caused by a non-specific mitogen of no immunological significance.
The third explanation could not apply to the mixed-cell reaction, and appears very unlikely in the case of tissue extracts, in view of the fact that no significant stimulation occurs using extracts ofnormal autologous spleen.
In the mixed-cell reactions, it is not possible to be certain whether a primary or secondary immune reaction is at work, but the latter appears at least to contribute, in view of the finding that the blastogenic response to leukaemic cells can be increased by immunization with irradiated leukaemic cells during remission (Powles et al., 1971) .
It has been generally thought that subcellular preparations of disrupted cells stimulate allogeneic lymphocytes poorly or not at all (Hardy, Ling and Knight, 1969) , and that lymphocytic blastogenesis to a solubilized extract represents a secondary immune response.
The situation with tumour extracts is more complicated, in that while some investigators found that tumour extracts do not produce stimulation of normal lymphocytes (Jehn, 1970; Vanky et al., 1974) , Dean et al. (1975) have recently demonstrated that breast carcinoma extracts can stimulate lymphocytes from normal individuals. They regarded this as a primary immune response to normal alloantigens in the extract, and concluded that investigation of blastogenic responses to breast carcinoma should be restricted to autologous situations. Similar results are evident from the present study, in which blastogenesis can be induced in normal allogeneic lymphocytes by spleen extracts with or without tumour deposits. As no significant stimulation occurs in autologous lymphocytes in response to tumour-free splenic extracts, the interpretation that autologous blastogenesis produced by tumour-containing extracts represents an immunological event, remains valid, but it is not possible to distinguish between a primary and secondary immune response. The leucocyte migration inhibition factor assay is influenced by alloantigens to a lesser degree (McCoy et al., 1974) , and may prove to be a more suitable index of heterologous reactions.
The degree of lymphocytic stimulation by whole tumour cells and homogenates is less than that obtained by stimulation with allogeneic lymphocytes, with some individual exceptions (Powles et al., 1971) , indicating that, generally speaking, the antigenic difference between tumour cells and autologous somatic cells is less than the antigenic difference between cells of unrelated individuals. It appears, however, that at least in leukaemia, the difference is sufficient to make immunotherapy using killed autologous tumour cells a realistic proposition (Powles et al. 1973) .
If immunotherapy using tumour cells or extracts should be considered for the therapy of malignant lymphomas, laboratory evidence of immunological differences between host and tumour cells is a useful prerequisite to providing a rational basis for treatment.
